◎ Sugi Atlas

Atlas / Drug / Rituximab

Rituximab

drug
On this page

Also known as ABP-798ABP798Bi 695500Bi-695500BI695500BlitzimaCT-P10GP-2013Gp2013HS-006HS-006 (RITUXIMAB BIOSIMILAR)HS006IDEC-102IDEC-C 2B8IDEC-C2B8IDEC102MabtheraMabthera rituxanMk-8808Pf-05280586

Summary

Rituximab (CHEMBL1201576) is an approved antibody (ATC L01FA01) targeting MS4A1; indicated across 152 conditions including non-hodgkin lymphoma and rheumatoid arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FA01
  • Targets: 1 (MS4A1)
  • Indications: 152 conditions
  • Clinical trials: 1,909

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201576
NameRituximab
TypeAntibody
Max phase4
ATCL01FA01

Also known as: ABP-798, ABP798, Bi 695500, Bi-695500, BI695500, Blitzima, CT-P10, GP-2013, Gp2013, HS-006, HS-006 (RITUXIMAB BIOSIMILAR), HS006

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
MS4A1CD20 (membrane-spanning 4-domains, subfamily A, member 1)Binding8.510%P11836

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MS4A1.

Dominant GO biological processes

GO termTargets
store-operated calcium entry1
humoral immune response1
cell surface receptor signaling pathway1
response to bacterium1
B cell differentiation1
B cell proliferation1
B cell activation1
B cell receptor signaling pathway1
protein tetramerization1
calcium ion import into cytosol1
positive regulation of calcium ion import across plasma membrane1

Indications & clinical

Indications

21 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
non-Hodgkin lymphoma4MONDO:0018908EFO:0005952
rheumatoid arthritis4MONDO:0008383EFO:0000685
granulomatosis with polyangiitis4MONDO:0012105EFO:0005297
B-cell chronic lymphocytic leukemia4MONDO:0004948EFO:0000095
acute lymphoblastic leukemia4MONDO:0004967EFO:0000220
neoplasm4MONDO:0005070EFO:0000616
microscopic polyangiitis4MONDO:0019124EFO:1000784
pemphigus vulgaris4MONDO:0008219EFO:0004719
pemphigus4MONDO:0006594EFO:1000749
vasculitis4MONDO:0018882EFO:0006803
Hodgkins lymphoma3MONDO:0004952EFO:0000183
lymphoma3MONDO:0005062EFO:0000574
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
MALT lymphoma3MONDO:0007650EFO:0000191
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
leukemia3MONDO:0005059EFO:0000565
mantle cell lymphoma3MONDO:0018876EFO:1001469
Burkitt lymphoma3MONDO:0007243EFO:0000309
lymphoid leukemia3MONDO:0005402EFO:0004289
marginal zone lymphoma3MONDO:0017604EFO:1000630
follicular lymphoma3MONDO:0018906MONDO:0018906

112 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
graft versus host disease3MONDO:0013730EFO:0004599
myalgic encephalomeyelitis/chronic fatigue syndrome3MONDO:0005404EFO:0004540
membranous glomerulonephritis3MONDO:0005376EFO:0004254
kidney disorder3MONDO:0005240EFO:0003086
myasthenia gravis3MONDO:0009688EFO:0004991
nephrotic syndrome3MONDO:0005377EFO:0004255
relapsing-remitting multiple sclerosis3MONDO:0005314EFO:0003929
anti-neutrophil antibody associated vasculitis3MONDO:0005435EFO:0004826
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
proteinuria3MONDO:0003634HP:0000093
bullous pemphigoid3MONDO:0019082EFO:0007187
interstitial lung disease3MONDO:0015925EFO:0004244
lupus nephritis3MONDO:0005556EFO:0005761
autoimmune hemolytic anemia3MONDO:0020108EFO:1001264
immune system disorder3MONDO:0005046EFO:0000540
Waldenstrom macroglobulinemia3MONDO:0100280EFO:0009441
polyneuropathy3MONDO:0001824EFO:0009562
chronic inflammatory demyelinating polyradiculoneuropathy3MONDO:0006702EFO:1000868
thrombotic thrombocytopenic purpura3MONDO:0018896MONDO:0018896
Guillain-Barre syndrome, familial3MONDO:0007691EFO:0009538
multiple sclerosis3MONDO:0005301MONDO:0005301
membranoproliferative glomerulonephritis3MONDO:0002461MONDO:0018904
lung disorder3MONDO:0005275EFO:0003818
polymyalgia rheumatica3MONDO:0019735EFO:0008518
systemic lupus erythematosus3MONDO:0007915MONDO:0007915
mental disorder3MONDO:0005084EFO:0000677
immunoglobulin A vasculitis3MONDO:0019167EFO:1000965
systemic sclerosis2MONDO:0005100EFO:0000717
metastatic melanoma2MONDO:0005191EFO:0002617
neuromyelitis optica2MONDO:0019100EFO:0004256
Sjogren syndrome2MONDO:0010030EFO:0000699
focal segmental glomerulosclerosis2MONDO:0100313EFO:0004236
ulcerative colitis2MONDO:0005101EFO:0000729
Behcet disease2MONDO:0007191EFO:0003780
chronic progressive multiple sclerosis2MONDO:0005284EFO:0003840
peripheral neuropathy2MONDO:0005244EFO:0003100
myelodysplastic syndrome2MONDO:0018881EFO:0000198
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
chronic myeloid leukemia2MONDO:0011996EFO:0000339
cutaneous melanoma2MONDO:0005012EFO:0000389
juvenile dermatomyositis2MONDO:0008054EFO:0000557
idiopathic pulmonary fibrosis2MONDO:0800504EFO:0000768
pneumococcal infection2MONDO:0005114EFO:0000772
plasma cell myeloma2MONDO:0009693EFO:0001378
lymphoid neoplasm2MONDO:0005157EFO:0001642
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
heart failure2MONDO:0005252EFO:0003144
pancreatic neoplasm2MONDO:0021040EFO:0003860
breast neoplasm2MONDO:0021100EFO:0003869
gastric neoplasm2MONDO:0021085EFO:0003897
ankylosing spondylitis2MONDO:0005306EFO:0003898
colonic neoplasm2MONDO:0005401EFO:0004288
eosinophilic granulomatosis with polyangiitis2MONDO:0015943EFO:0007208
Japanese encephalitis2MONDO:0019209EFO:0007332
mast cell leukemia2MONDO:0020334EFO:0007359
stiff-person syndrome2MONDO:0008491EFO:0007498
diabetic neuropathy2MONDO:0006626EFO:1000783
hairy cell leukemia2MONDO:0018935EFO:1000956
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
acute myeloid leukemia2MONDO:0018874EFO:0000222
AIDS2MONDO:0012268EFO:0000765
primary progressive multiple sclerosis2MONDO:0000451EFO:0008520
secondary progressive multiple sclerosis2MONDO:0000450EFO:0008522
Langerhans cell histiocytosis2MONDO:0018310EFO:1000318
chronic myelomonocytic leukemia2MONDO:0020311EFO:1001779
kidney failure2MONDO:0001106EFO:1002048
aplastic anemia2MONDO:0015909HP:0001915
blast phase chronic myelogenous leukemia, BCR-ABL1 positive2MONDO:0006115EFO:1000131
prolymphocytic leukemia2MONDO:0001023MONDO:0001023
pulmonary alveolar proteinosis2MONDO:0001437MONDO:0001437
hemolytic-uremic syndrome2MONDO:0001549MONDO:0001549
glomerulonephritis2MONDO:0002462MONDO:0002462
Castleman disease2MONDO:0015564MONDO:0015564
lung neoplasm2MONDO:0021117MONDO:0021117
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
human T-lymphotropic virus 1 infectious disease2MONDO:0005801EFO:0007316
spinal cord disorder2MONDO:0002545HP:0002196
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
hemophilia A2MONDO:0010602MONDO:0010602
sickle cell disease2MONDO:0011382MONDO:0011382
lymphoproliferative syndrome2MONDO:0016537MONDO:0016537
sarcoidosis2MONDO:0019338MONDO:0019338
rheumatic heart disease2MONDO:0006955EFO:1001161
B-cell non-Hodgkin lymphoma2MONDO:0015759EFO:1001938
hepatocellular carcinoma2MONDO:0007256EFO:0000182
plasma cell neoplasm2MONDO:0004959EFO:0000200
melanoma2MONDO:0005105EFO:0000756
viral infectious disease2MONDO:0005108EFO:0000763
psychotic disorder2MONDO:0005485EFO:0005407
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
chronic kidney disease2MONDO:0005300MONDO:0024327
Crohn disease1MONDO:0005011EFO:0000384
psoriatic arthritis1MONDO:0011849EFO:0003778
autoimmune disease1MONDO:0007179EFO:0005140
urticaria1MONDO:0005492EFO:0005531
opsoclonus-myoclonus syndrome1MONDO:0015247EFO:1001383
primary biliary cholangitis1MONDO:0005388EFO:1001486
myopathy1MONDO:0005336EFO:0004145
ocular cicatricial pemphigoid1MONDO:0008109EFO:0008610
macular degeneration1MONDO:0003004EFO:0009606
mycosis fungoides1MONDO:0009691EFO:1001051
squamous cell carcinoma1MONDO:0005096EFO:0000707
encephalomyelitis1MONDO:0005156EFO:0001423
hematologic disorder1MONDO:0005570HP:0001871
scleritis1MONDO:0001718MONDO:0001718
Fanconi anemia1MONDO:0019391MONDO:0019391
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
Graves disease1MONDO:0005364EFO:0004237
gout1MONDO:0005393EFO:0004274
primary effusion lymphoma1MONDO:0018842EFO:1000491

18 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,909.

Phase distribution

PhaseTrials
PHASE2880
PHASE3339
PHASE1241
PHASE1/PHASE2217
Not specified110
PHASE463
PHASE2/PHASE341
EARLY_PHASE118

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04989491PHASE4RECRUITINGEvaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
NCT05207358PHASE4RECRUITINGMinimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
NCT05514015PHASE4RECRUITINGClinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
NCT05898308PHASE4RECRUITINGComparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
NCT06003283PHASE4RECRUITINGTapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06410833PHASE4RECRUITINGBelimumab After Rituximab in Resistant Primary Juvenile SS
NCT06611696PHASE4RECRUITINGAvacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
NCT06906549PHASE4RECRUITINGEvaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT07270835PHASE4RECRUITINGZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
NCT07451847PHASE4NOT_YET_RECRUITINGComparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
NCT00090038PHASE4COMPLETEDEffect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma
NCT00131313PHASE4UNKNOWNEfficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00198978PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00199004PHASE4COMPLETEDTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199082PHASE4COMPLETEDNewly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT00462345PHASE4COMPLETEDA Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
NCT00476164PHASE4COMPLETEDStudy of Rituximab to Treat Chronic Renal Transplant Rejection
NCT00498368PHASE4COMPLETEDRituximab in Progressive Immunoglobulin A (IgA) Nephropathy
NCT00701129PHASE4COMPLETEDAn Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
NCT00753597PHASE4COMPLETEDRescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)
NCT00782821PHASE4COMPLETEDRandomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
NCT00797810PHASE4UNKNOWNIntensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin’s Lymphoma in Adults
NCT00820469PHASE4COMPLETEDStudy of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
NCT00908583PHASE4COMPLETEDDesensitization in Kidney Transplantation
NCT01021735PHASE4COMPLETEDOptimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
NCT01088724PHASE4COMPLETEDFludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
NCT01095172PHASE4UNKNOWNRituxiMab INDuction in Renal Transplantation
NCT01271010PHASE4TERMINATEDA Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
NCT01280682PHASE4COMPLETEDImmune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
NCT01283386PHASE4TERMINATEDA Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
NCT01295151PHASE4COMPLETEDSWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
NCT01312064PHASE4TERMINATEDDe Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
NCT01358253PHASE4COMPLETEDRituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
NCT01382940PHASE4COMPLETEDA Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
NCT01593332PHASE4COMPLETEDLow Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
NCT01638715PHASE4COMPLETEDA Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
NCT01765374PHASE4COMPLETEDStudy of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis
NCT02040116PHASE4COMPLETEDStudy Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
NCT02115997PHASE4COMPLETEDA Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener’s Granulomatosis or Microscopic Polyangitis
NCT02169219PHASE4COMPLETEDPilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02198248PHASE4UNKNOWNLow-dose Glucocorticoid Vasculitis Induction Study
NCT02378298PHASE4COMPLETEDRituximab (RTX) Therapy in Patients With Active TAO
NCT02382575PHASE4UNKNOWNEfficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome
NCT02525172PHASE4UNKNOWNImmune Modulation Therapy for Pompe Disease
NCT02571842PHASE4UNKNOWNRituximab in Recurrent IgA Nephropathy
NCT02626845PHASE4TERMINATEDRituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
NCT02731560PHASE4COMPLETEDRituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)
NCT02749292PHASE4TERMINATEDMaintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
NCT02752815PHASE4UNKNOWNReduced Chemotherapy in Low Risk DLBCL
NCT02844322PHASE4COMPLETEDThe Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
NCT02858804PHASE4COMPLETEDEDOCH Alternating With DHAP for New Diagnosed Younger MCL
NCT03258866PHASE4COMPLETEDThe Study of Different Dose Rituximab in the Treatment of ITP
NCT03384277PHASE4COMPLETEDTrial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
NCT03598725PHASE4UNKNOWNLow-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China
NCT04033276PHASE4COMPLETEDIVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
NCT04256252PHASE4COMPLETEDRituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)
NCT04525729PHASE4COMPLETEDRituximab and RASi in Patients with IgAN
NCT05494593PHASE4WITHDRAWNA Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
NCT05824390PHASE4UNKNOWNA Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
NCT05828147PHASE4UNKNOWNAnti-CD20 Antibodies for Treatment of SLE-PAH
NCT05861297PHASE4UNKNOWNImmune Thrombocytopenia Management in Adults
NCT06015750PHASE4WITHDRAWNMitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
NCT00877214PHASE3ACTIVE_NOT_RECRUITINGSignificance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
NCT01886872PHASE3ACTIVE_NOT_RECRUITINGRituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT02003222PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02048813PHASE3ACTIVE_NOT_RECRUITINGIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02405676PHASE2/PHASE3ACTIVE_NOT_RECRUITINGBNHL-2015 for Children or Adolescents in China
NCT02970318PHASE3ACTIVE_NOT_RECRUITINGA Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02972840PHASE3ACTIVE_NOT_RECRUITINGA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT03150693PHASE3RECRUITINGInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03206671PHASE3ACTIVE_NOT_RECRUITINGTreatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
NCT03267433PHASE3ACTIVE_NOT_RECRUITINGRituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03295383PHASE3RECRUITINGRandomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
NCT03336333PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03414502PHASE3RECRUITINGTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03984448PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT04002297PHASE3ACTIVE_NOT_RECRUITINGA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04061512PHASE2/PHASE3RECRUITINGRituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia
NCT04075292PHASE3ACTIVE_NOT_RECRUITINGStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04212013PHASE3ACTIVE_NOT_RECRUITINGA Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
NCT04224493PHASE3ACTIVE_NOT_RECRUITINGA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04384484PHASE3ACTIVE_NOT_RECRUITINGStudy to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04404283PHASE3ACTIVE_NOT_RECRUITINGBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04529772PHASE3ACTIVE_NOT_RECRUITINGA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04578639PHASE3ACTIVE_NOT_RECRUITINGOcrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
NCT04666038PHASE3ACTIVE_NOT_RECRUITINGStudy of LOXO-305 (Pirtobrutinib) Versus Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04680052PHASE3ACTIVE_NOT_RECRUITINGA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04688788PHASE3ACTIVE_NOT_RECRUITINGNon-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT04712097PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04745728PHASE3RECRUITINGDifferent Immunosuppressive Treatment in iMN
NCT04759586PHASE3ACTIVE_NOT_RECRUITINGNivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04799275PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04824092PHASE3ACTIVE_NOT_RECRUITINGTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04833114PHASE3ACTIVE_NOT_RECRUITINGPolatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
NCT04871191PHASE3RECRUITINGStudy of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
NCT04965493PHASE3ACTIVE_NOT_RECRUITINGA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT05023980PHASE3ACTIVE_NOT_RECRUITINGA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05057468PHASE3RECRUITINGSecond-line Treatment of Primary Autoimmune Hemolytic Anemia
NCT05100862PHASE3RECRUITINGA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomerefseqtranscriptuniprot